Gurkamal Chatta MD

Oncology•Buffalo, NY

Professor of Oncology Clinical Chief of Genitourinary Medicine Roswell Park Cancer Institute

Join to View Full Profile

Elm and Carlton StBuffalo, NY 14263
Phone+1 716-845-2300
Fax+1 716-845-3519

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1995 - 1996
University of WashingtonFellowship, Geriatric Medicine (Internal Medicine), 1988 - 1992
Aurora Health CareResidency, Internal Medicine, 1986 - 1988
SSM Health/Saint Louis University School of MedicineResidency, Pediatrics, 1985 - 1985
Delhi University College of Medical SciencesClass of 1979

Certifications & Licensure

NY State Medical License 2016 - 2027
AK State Medical License 2015 - 2026
WA State Medical License 1988 - 2025
PA State Medical License 2001 - 2024
AR State Medical License 1997 - 2001
WI State Medical License 1986 - 1989
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification HealthSentry EHR, Cerner Corporation, 2013

Clinical Trials

Calcitriol Plus Dexamethasone in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 1999 Jun 01
Completed
Phase 1
Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) Start of enrollment: 2006 Mar 01
Completed
Phase 2
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2021 Apr 15
Withdrawn
Phase 1, Phase 2
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2019 Aug 02
Completed
Phase 1
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors Start of enrollment: 2019 May 02
RECRUITING
NA
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery Start of enrollment: 2019 Nov 29
ACTIVE_NOT_RECRUITING
PHASE2
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy Start of enrollment: 2019 Jun 20
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

56 citations
Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells.
Ravikumar Muthuswamy, John M. Corman, Kathryn Dahl, Gurkamal Chatta, Pawel Kalinski
The Prostate. 2016-09-01
2 citations
Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers.
Amy Soni, Sherrie L. Aspinall, Xinhua Zhao, Chester B. Good, Francesca E. Cunningham
Oncology Research. 2015-11-25
47 citations
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy
Przemyslaw Twardowski, Jan H. Beumer, Chien-Shing Chen, Andrew S. Kraft, Gurkamal Chatta
Anti-Cancer Drugs. 2013-08-01

Press Mentions

Does the Common Cold Virus Kill Bladder Cancer?July 24th, 2019
Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer CenterMay 13th, 2019
Clinical Trial Hopes to Provide Less Toxic Treatment for Prostate CancerOctober 18th, 2017